Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crescent Biopharma, Inc. - Common Stock (NQ:CBIO)

14.71 +0.23 (+1.62%)
Streaming Delayed Price Updated: 12:57 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Crescent Biopharma, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at June Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at May Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at March Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
From Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at November Investor Conferences
From Crescent Biopharma
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.